Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2)

NCT07220629 · Active, not recruiting

Last updated 2026-05-28

This clinical trial is testing the safety of adding the experimental drug NT-0796 to semaglutide in adults with obesity.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Participants 82 people

Who can join Ages 18–75 · all sexes

Timeline Started 2025-10 · est. completion 2026-08

Where 9 sites · United States

What this study is testing ClinicalTrials.gov NCT07220629 ↗

Description as written by the study sponsor.

A Phase 2a randomized, double-blind, placebo-controlled, parallel-group, multicenter study to explore the safety and efficacy of NT-0796 as an adjunct to semaglutide in participants with obesity over a 6 months treatment period.

Treatments tested

NT-0796 Drug

Orally administered capsules
Placebo Drug

Orally administered capsules

Main thing measured	Assess the safety and tolerability of NT-0796 as an adjunct to semaglutide in participants with obesity by assessing AEs and SAEs, symptoms of nausea and vomiting, clinical laboratory parameters, vital signs and ECGs.
Sponsor	NodThera Limited
Conditions studied	Obesity
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07220629 ↗